Atossa Genetics is a clinical-stage pharmaceutical company focused on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its patented intraductal microcatheters that deliver pharmaceuticals through the breast milk ducts. Atossa has initiated a Phase 2 clinical study using its microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer.

Oral endoxifen is the Company's second development program. Endoxifen is an active metabolite of tamoxifen, an FDA approved drug for breast cancer patients to prevent recurrence as well as new breast cancer.

Atossa Genetics is passionate about improving breast health and the overall well-being and health of women and men.

TypePublic
HQSeattle, US
Founded2009
Size (employees)18 (est)
Websiteatossagenetics.com
Atossa Genetics was founded in 2009 and is headquartered in Seattle, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Atossa Genetics

Steven C. Quay

Steven C. Quay

Chairman of the Board and Chief Executive Officer
Kyle Guse

Kyle Guse

Chief Financial Officer, General Counsel and Secretary
Janet Rose Rea

Janet Rose Rea

Senior Vice President, Regulatory, Quality, Clinical Affairs
Show more

Atossa Genetics Office Locations

Atossa Genetics has an office in Seattle
Seattle, US (HQ)
4105 E Madison St
Show all (1)
Report incorrect company information

Atossa Genetics Financials and Metrics

Atossa Genetics Revenue

USD

Net income (Q2, 2018)

(6 m)

EBIT (Q2, 2018)

(6 m)

Market capitalization (20-Sep-2018)

8.6 m

Closing stock price (20-Sep-2018)

1.6

Cash (30-Jun-2018)

15.2 m
Atossa Genetics's current market capitalization is $8.6 m.
Annual
USDFY, 2017

General and administrative expense

4.9 m

R&D expense

2.3 m

Operating expense total

7.6 m

EBIT

(7.6 m)
Quarterly
USDQ2, 2018

General and administrative expense

4.1 m

R&D expense

1.9 m

Operating expense total

6 m

EBIT

(6 m)
Annual
USDFY, 2017

Cash

7.2 mwdxefcqufszuzezftuxetqsqxt

Current Assets

7.9 m

Total Assets

8.2 m

Accounts Payable

334.9 k
Quarterly
USDQ2, 2018

Cash

15.2 m

Current Assets

16.4 m

Total Assets

16.6 m

Accounts Payable

191.2 k
Annual
USDFY, 2017

Net Income

(8.1 m)

Depreciation and Amortization

129 k

Accounts Payable

80.6 k

Cash From Operating Activities

(6.6 m)
Quarterly
USDQ2, 2018

Net Income

(6 m)

Depreciation and Amortization

17.8 k

Accounts Payable

(143.7 k)

Cash From Operating Activities

(4.2 m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Atossa Genetics Online and Social Media Presence

Embed Graph
Report incorrect company information

Atossa Genetics News and Updates

Atossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDT

SEATTLE, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, will host a conference call on September 13, 2018 at 10 am EDT to discuss pre…

BRIEF-Intracoastal Capital Reports 5.9 Pct passive Stake In Atossa Genetics Inc, As Of April 23, 2018

* INTRACOASTAL CAPITAL LLC REPORTS 5.9 PERCENT PASSIVE STAKE IN ATOSSA GENETICS INC, AS OF APRIL 23, 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2Ki2uGi) Further company coverage:
Report incorrect company information

Atossa Genetics Company Life and Culture

Report incorrect company information